5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients

BACKGROUND: Although R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) remains the standard chemotherapy regimen for diffuse large B cell lymphoma (DLBCL) patients, not all patients are responsive to the scheme, and there is no effective method to predict treatment respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hang-Yu, Zhang, Wei-Long, Zhang, Lei, Yang, Ping, Li, Fang, Yang, Ze-Ruo, Wang, Jing, Pang, Meng, Hong, Yun, Yan, Changjian, Li, Wei, Liu, Jia, Xu, Nuo, Chen, Long, Xiao, Xiu-Bing, Qin, Yan, He, Xiao-Hui, Liu, Hui, Zhu, Hai-Chuan, He, Chuan, Lin, Jian, Jing, Hong-Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879534/
https://www.ncbi.nlm.nih.gov/pubmed/33573703
http://dx.doi.org/10.1186/s13148-020-00973-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879534/
https://www.ncbi.nlm.nih.gov/pubmed/33573703
http://dx.doi.org/10.1186/s13148-020-00973-8

Ejemplares similares